GlassScriptPhysician profile
Niculae Ciobanu
NPI 1851598361
$7,051.66
in general payments reported to CMS, 2019-2025
48 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,505 · 2020: $1,290 · 2021: $1,187 · 2022: $181 · 2023: $664 · 2024: $109 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.74 |
| Education | $197.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $859.67 | 2019-2023 | |
| Amgen INC. | $533.71 | 2019-2023 | Nplate, Vectibix, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $496.60 | 2019-2021 | |
| Genzyme Corporation | $406.99 | 2019-2021 | |
| Lilly USA, LLC | $388.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $320.65 | 2019-2021 | |
| Janssen Biotech, INC. | $302.68 | 2019-2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $294.87 | 2019-2021 | |
| Incyte Corporation | $288.63 | 2019-2025 | |
| Puma Biotechnology, INC. | $245.44 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.91 | 2019-2023 | Ninlaro |
| Rigel Pharmaceuticals, INC. | $201.13 | 2019-2023 | Rezlidhia, Tavalisse |
| Celgene Corporation | $198.12 | 2019-2020 | |
| Seagen INC. | $174.01 | 2019-2021 | |
| Eisai INC. | $155.31 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niculae Ciobanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.